Gastrointestinal and cutaneous AIDS-related Kaposi's sarcoma: different activity of liposomal doxorubicin according to location of lesions
Kaposi's sarcoma (KS) continues to be a frequent neoplasm in third world AIDS patients. We carried out a prospective study to evaluate the effectiveness of liposomal doxorubicin (LD) in gastrointestinal KS patients as well as its differential clinical activity depending on the location of the l...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer care 2005-07, Vol.14 (3), p.264-266 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 266 |
|---|---|
| container_issue | 3 |
| container_start_page | 264 |
| container_title | European journal of cancer care |
| container_volume | 14 |
| creator | HERNÁNDEZ-MORALES, D.E. HERNÁNDEZ-ZACCARO, A.E. |
| description | Kaposi's sarcoma (KS) continues to be a frequent neoplasm in third world AIDS patients. We carried out a prospective study to evaluate the effectiveness of liposomal doxorubicin (LD) in gastrointestinal KS patients as well as its differential clinical activity depending on the location of the lesions. The study included 15 male AIDS patients aged between 25 and 35 years (mean: 27 years) with more than 25 cutaneous lesions and extensive gastrointestinal KS. They were treated with LD, 20 mg/m2 every 21 days, for six cycles. Eleven (73%) of the patients obtained a complete response of the gastrointestinal KS lesions and four (27%) a partial response. Regarding cutaneous lesions, only two (13%) of the patients reached a complete response, six (40%) a partial response and seven (47%) stabilized their disease. By applying Fisher's test we found a significant difference (P |
| doi_str_mv | 10.1111/j.1365-2354.2005.00567.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_764261134</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>57037277</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4947-784d6d167bf21cfe15154a94b74cecfc67a1d38a89ef977992fd1b33bd6f95333</originalsourceid><addsrcrecordid>eNqNkc1uEzEUhUcIREPhFZDFgq5mGP-PEZsqLaEiwKIgJDaWxz_IYTJObQ8kr8BT4zRRkVgAlq58pfudI917qgrAtoHlvVg1EDNaI0xJg9qWNqUYb7b3qtnd4H41awWDNSUIn1SPUlq1LcRQkIfVCaSCIsHhrPq5UCnH4MdsU_ajGoAaDdBTVqMNUwLnVxfXdbSDytaAt2oTkj9LIKmow1q9BMY7Z6MdM1A6--8-70BwYPCFK_MBmLANceq99mMhdIjGj19BDmAIWmUfxlvcptKlx9UDp4Zknxz_0-rT68uP8zf18sPian6-rDURhNe8I4YZyHjvENTOQgopUYL0nGirnWZcQYM71QnrBOdCIGdgj3FvmBMUY3xanR18NzHcTGVtufZJ22E4rCw5I4hBiEkhn_-VZFygDjH2T5DyFnPEeQGf_QGuwhTL2ZOEQmDRYiIK1B0gHUNK0Tq5iX6t4k7CVu7zlyu5j1nuY5b7_OVt_nJbpE-P_lO_tua38Bh4AV4dgB9-sLv_NpaX83lpirw-yH3KdnsnV_FbOQbmVH5-v5DkHW-_LNm1vMC_AA4Czv0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>199390349</pqid></control><display><type>article</type><title>Gastrointestinal and cutaneous AIDS-related Kaposi's sarcoma: different activity of liposomal doxorubicin according to location of lesions</title><source>MEDLINE</source><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>Wiley Online Library All Journals</source><creator>HERNÁNDEZ-MORALES, D.E. ; HERNÁNDEZ-ZACCARO, A.E.</creator><creatorcontrib>HERNÁNDEZ-MORALES, D.E. ; HERNÁNDEZ-ZACCARO, A.E.</creatorcontrib><description>Kaposi's sarcoma (KS) continues to be a frequent neoplasm in third world AIDS patients. We carried out a prospective study to evaluate the effectiveness of liposomal doxorubicin (LD) in gastrointestinal KS patients as well as its differential clinical activity depending on the location of the lesions. The study included 15 male AIDS patients aged between 25 and 35 years (mean: 27 years) with more than 25 cutaneous lesions and extensive gastrointestinal KS. They were treated with LD, 20 mg/m2 every 21 days, for six cycles. Eleven (73%) of the patients obtained a complete response of the gastrointestinal KS lesions and four (27%) a partial response. Regarding cutaneous lesions, only two (13%) of the patients reached a complete response, six (40%) a partial response and seven (47%) stabilized their disease. By applying Fisher's test we found a significant difference (P < 0.00035) when comparing the effectiveness of LD in gastrointestinal lesions in relation to cutaneous lesions. We conclude that LD is more effective in gastrointestinal KS and can be recommended in patients in third world countries with extensive gastrointestinal lesions.</description><identifier>ISSN: 0961-5423</identifier><identifier>EISSN: 1365-2354</identifier><identifier>DOI: 10.1111/j.1365-2354.2005.00567.x</identifier><identifier>PMID: 15952971</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Adult ; AIDS ; Antibiotics, Antineoplastic - administration & dosage ; Clinical effectiveness ; cutaneous ; Developing countries ; Doxorubicin ; Doxorubicin - administration & dosage ; Drug Administration Schedule ; gastrointestinal ; Gastrointestinal Neoplasms - drug therapy ; Humans ; Kaposi's sarcoma ; liposomal doxorubicin ; Liposomes ; Male ; Nursing ; Prospective Studies ; Sarcoma, Kaposi - drug therapy ; Skin Neoplasms - drug therapy ; Treatment ; Treatment Outcome</subject><ispartof>European journal of cancer care, 2005-07, Vol.14 (3), p.264-266</ispartof><rights>Copyright Blackwell Publishing Jul 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4947-784d6d167bf21cfe15154a94b74cecfc67a1d38a89ef977992fd1b33bd6f95333</citedby><cites>FETCH-LOGICAL-c4947-784d6d167bf21cfe15154a94b74cecfc67a1d38a89ef977992fd1b33bd6f95333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2354.2005.00567.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2354.2005.00567.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,31000,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15952971$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HERNÁNDEZ-MORALES, D.E.</creatorcontrib><creatorcontrib>HERNÁNDEZ-ZACCARO, A.E.</creatorcontrib><title>Gastrointestinal and cutaneous AIDS-related Kaposi's sarcoma: different activity of liposomal doxorubicin according to location of lesions</title><title>European journal of cancer care</title><addtitle>Eur J Cancer Care (Engl)</addtitle><description>Kaposi's sarcoma (KS) continues to be a frequent neoplasm in third world AIDS patients. We carried out a prospective study to evaluate the effectiveness of liposomal doxorubicin (LD) in gastrointestinal KS patients as well as its differential clinical activity depending on the location of the lesions. The study included 15 male AIDS patients aged between 25 and 35 years (mean: 27 years) with more than 25 cutaneous lesions and extensive gastrointestinal KS. They were treated with LD, 20 mg/m2 every 21 days, for six cycles. Eleven (73%) of the patients obtained a complete response of the gastrointestinal KS lesions and four (27%) a partial response. Regarding cutaneous lesions, only two (13%) of the patients reached a complete response, six (40%) a partial response and seven (47%) stabilized their disease. By applying Fisher's test we found a significant difference (P < 0.00035) when comparing the effectiveness of LD in gastrointestinal lesions in relation to cutaneous lesions. We conclude that LD is more effective in gastrointestinal KS and can be recommended in patients in third world countries with extensive gastrointestinal lesions.</description><subject>Adult</subject><subject>AIDS</subject><subject>Antibiotics, Antineoplastic - administration & dosage</subject><subject>Clinical effectiveness</subject><subject>cutaneous</subject><subject>Developing countries</subject><subject>Doxorubicin</subject><subject>Doxorubicin - administration & dosage</subject><subject>Drug Administration Schedule</subject><subject>gastrointestinal</subject><subject>Gastrointestinal Neoplasms - drug therapy</subject><subject>Humans</subject><subject>Kaposi's sarcoma</subject><subject>liposomal doxorubicin</subject><subject>Liposomes</subject><subject>Male</subject><subject>Nursing</subject><subject>Prospective Studies</subject><subject>Sarcoma, Kaposi - drug therapy</subject><subject>Skin Neoplasms - drug therapy</subject><subject>Treatment</subject><subject>Treatment Outcome</subject><issn>0961-5423</issn><issn>1365-2354</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqNkc1uEzEUhUcIREPhFZDFgq5mGP-PEZsqLaEiwKIgJDaWxz_IYTJObQ8kr8BT4zRRkVgAlq58pfudI917qgrAtoHlvVg1EDNaI0xJg9qWNqUYb7b3qtnd4H41awWDNSUIn1SPUlq1LcRQkIfVCaSCIsHhrPq5UCnH4MdsU_ajGoAaDdBTVqMNUwLnVxfXdbSDytaAt2oTkj9LIKmow1q9BMY7Z6MdM1A6--8-70BwYPCFK_MBmLANceq99mMhdIjGj19BDmAIWmUfxlvcptKlx9UDp4Zknxz_0-rT68uP8zf18sPian6-rDURhNe8I4YZyHjvENTOQgopUYL0nGirnWZcQYM71QnrBOdCIGdgj3FvmBMUY3xanR18NzHcTGVtufZJ22E4rCw5I4hBiEkhn_-VZFygDjH2T5DyFnPEeQGf_QGuwhTL2ZOEQmDRYiIK1B0gHUNK0Tq5iX6t4k7CVu7zlyu5j1nuY5b7_OVt_nJbpE-P_lO_tua38Bh4AV4dgB9-sLv_NpaX83lpirw-yH3KdnsnV_FbOQbmVH5-v5DkHW-_LNm1vMC_AA4Czv0</recordid><startdate>200507</startdate><enddate>200507</enddate><creator>HERNÁNDEZ-MORALES, D.E.</creator><creator>HERNÁNDEZ-ZACCARO, A.E.</creator><general>Blackwell Science Ltd</general><general>Hindawi Limited</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>ASE</scope><scope>FPQ</scope><scope>FR3</scope><scope>K6X</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7QJ</scope><scope>7X8</scope></search><sort><creationdate>200507</creationdate><title>Gastrointestinal and cutaneous AIDS-related Kaposi's sarcoma: different activity of liposomal doxorubicin according to location of lesions</title><author>HERNÁNDEZ-MORALES, D.E. ; HERNÁNDEZ-ZACCARO, A.E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4947-784d6d167bf21cfe15154a94b74cecfc67a1d38a89ef977992fd1b33bd6f95333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>AIDS</topic><topic>Antibiotics, Antineoplastic - administration & dosage</topic><topic>Clinical effectiveness</topic><topic>cutaneous</topic><topic>Developing countries</topic><topic>Doxorubicin</topic><topic>Doxorubicin - administration & dosage</topic><topic>Drug Administration Schedule</topic><topic>gastrointestinal</topic><topic>Gastrointestinal Neoplasms - drug therapy</topic><topic>Humans</topic><topic>Kaposi's sarcoma</topic><topic>liposomal doxorubicin</topic><topic>Liposomes</topic><topic>Male</topic><topic>Nursing</topic><topic>Prospective Studies</topic><topic>Sarcoma, Kaposi - drug therapy</topic><topic>Skin Neoplasms - drug therapy</topic><topic>Treatment</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HERNÁNDEZ-MORALES, D.E.</creatorcontrib><creatorcontrib>HERNÁNDEZ-ZACCARO, A.E.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Engineering Research Database</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HERNÁNDEZ-MORALES, D.E.</au><au>HERNÁNDEZ-ZACCARO, A.E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gastrointestinal and cutaneous AIDS-related Kaposi's sarcoma: different activity of liposomal doxorubicin according to location of lesions</atitle><jtitle>European journal of cancer care</jtitle><addtitle>Eur J Cancer Care (Engl)</addtitle><date>2005-07</date><risdate>2005</risdate><volume>14</volume><issue>3</issue><spage>264</spage><epage>266</epage><pages>264-266</pages><issn>0961-5423</issn><eissn>1365-2354</eissn><abstract>Kaposi's sarcoma (KS) continues to be a frequent neoplasm in third world AIDS patients. We carried out a prospective study to evaluate the effectiveness of liposomal doxorubicin (LD) in gastrointestinal KS patients as well as its differential clinical activity depending on the location of the lesions. The study included 15 male AIDS patients aged between 25 and 35 years (mean: 27 years) with more than 25 cutaneous lesions and extensive gastrointestinal KS. They were treated with LD, 20 mg/m2 every 21 days, for six cycles. Eleven (73%) of the patients obtained a complete response of the gastrointestinal KS lesions and four (27%) a partial response. Regarding cutaneous lesions, only two (13%) of the patients reached a complete response, six (40%) a partial response and seven (47%) stabilized their disease. By applying Fisher's test we found a significant difference (P < 0.00035) when comparing the effectiveness of LD in gastrointestinal lesions in relation to cutaneous lesions. We conclude that LD is more effective in gastrointestinal KS and can be recommended in patients in third world countries with extensive gastrointestinal lesions.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>15952971</pmid><doi>10.1111/j.1365-2354.2005.00567.x</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0961-5423 |
| ispartof | European journal of cancer care, 2005-07, Vol.14 (3), p.264-266 |
| issn | 0961-5423 1365-2354 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_764261134 |
| source | MEDLINE; Applied Social Sciences Index & Abstracts (ASSIA); Wiley Online Library All Journals |
| subjects | Adult AIDS Antibiotics, Antineoplastic - administration & dosage Clinical effectiveness cutaneous Developing countries Doxorubicin Doxorubicin - administration & dosage Drug Administration Schedule gastrointestinal Gastrointestinal Neoplasms - drug therapy Humans Kaposi's sarcoma liposomal doxorubicin Liposomes Male Nursing Prospective Studies Sarcoma, Kaposi - drug therapy Skin Neoplasms - drug therapy Treatment Treatment Outcome |
| title | Gastrointestinal and cutaneous AIDS-related Kaposi's sarcoma: different activity of liposomal doxorubicin according to location of lesions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T11%3A16%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gastrointestinal%20and%20cutaneous%20AIDS-related%20Kaposi's%20sarcoma:%20different%20activity%20of%20liposomal%20doxorubicin%20according%20to%20location%20of%20lesions&rft.jtitle=European%20journal%20of%20cancer%20care&rft.au=HERN%C3%81NDEZ-MORALES,%20D.E.&rft.date=2005-07&rft.volume=14&rft.issue=3&rft.spage=264&rft.epage=266&rft.pages=264-266&rft.issn=0961-5423&rft.eissn=1365-2354&rft_id=info:doi/10.1111/j.1365-2354.2005.00567.x&rft_dat=%3Cproquest_cross%3E57037277%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=199390349&rft_id=info:pmid/15952971&rfr_iscdi=true |